EXP. 229_AC_RNAseq data of human cancer cell lines 94T778, SKBR3, AU565, SKMEL28 and A375 exposed to the selective MTOR inhibitor torkinib (PP242, Selleckchem, TX, USA) for 72 hours.

Drug concentrations were selected to halt cell cycle progression without affecting cell viability: 94T778 10 µM, A375, SKMEL28 and AU565 4 µM, SKBR3 0.8 µM. The pharmacologic inhibition of MTOR repressed expression of the homologous recombination (HR) and Fanconi Anemia (FA) pathways, and selectively high-fidelity but not error-prone DNA polymerases in all cancer cell lines sequenced Overall design: The experiment has been designed to understand the impact of MTOR inhibition on the expression profile of different genes involved in DNA repair.